BD Reaches Major Milestone for Rotarex™ Catheter System with First Patient Enrolled in XTRACT™ Registry to Advance Real-World Evidence in Peripheral Artery Disease

Core Insights - BD has enrolled the first patient in the XTRACT™ Registry, a study aimed at evaluating the real-world performance of the Rotarex™ Catheter System for treating peripheral artery disease (PAD) [1][2][4] Company Overview - BD is a leading global medical technology company focused on improving medical discovery, diagnostics, and care delivery [6] - The company employs over 70,000 individuals and operates in nearly every country, addressing significant global health challenges [6] XTRACT™ Registry Details - The XTRACT™ Registry is a prospective, multi-center, single-arm study designed to collect data on the Rotarex™ Catheter System's effectiveness in treating PAD [1][2] - The registry aims to enroll up to 600 patients across 100 clinical sites in the U.S., with follow-up evaluations at 30 days, six months, and 12 months post-procedure [3][4] Rotarex™ Catheter System Features - The Rotarex™ Catheter System utilizes three mechanisms of action to effectively remove plaque and thrombus, functioning as both an atherectomy and thrombectomy device [4] - The device is designed to enhance patient outcomes by modifying and detaching mixed morphology lesions while actively aspirating material away [4] Market Context - PAD affects over 21 million Americans and more than 200 million people globally, with untreated cases leading to serious cardiovascular complications [5]